Chonluten Research: The Glu-Asp-Gly Tripeptide and Its Very Small Literature

What is Chonluten?

What is Chonluten? A synthetic tripeptide, Glu-Asp-Gly (EDG), belonging to the short-peptide programme run from the St Petersburg Institute of Bioregulation and Gerontology since the 1970s. Like the rest of that family it shares the Glu-Asp core found in Epitalon (AEDG), Pinealon (EDR), Crystagen (EDP) and Cartalax (AED), differing in what sits on either side of it. Its developers assigned it to bronchial and lung tissue. That designation is their label, not an independent conclusion.

The single primary study that tests it describes it as “the Chonluten tripeptide, derived from bronchial epithelial cells” — language typical of this programme, in which a synthetic peptide is named after the tissue extract that preceded it. As the overview page puts it: an extract is not the synthetic peptide named after it, and establishing which of the two a given claim refers to is the first job when reading this corpus.

Chonluten is not Bronchogen

This distinction deserves its own heading because both compounds carry a lung assignment and the two names circulate interchangeably in secondary material online. They are different molecules:

The practical consequence is analytical. A 127 Da mass difference is large and unambiguous on a mass spectrum, so a certificate of analysis settles which compound is in a vial immediately. A product name does not. See Bronchogen research for that compound’s own page, which additionally documents a residue-order discrepancy inside its primary literature.

Reference data

Identity and form only, from the public chemical record for the all-L Glu-Asp-Gly tripeptide (PubChem CID 194641). No PubChem record carries “Chonluten” as a listed synonym; the sequence link is made from the primary literature cited below.

The “T-34” synonym in the chemical record is a small but genuine illustration of the traceability problem the overview page describes. The group’s papers frequently designate compounds by internal codes — T-31, T-38, D-7 and similar — without giving the sequence in the same paper, so a reader tracing a finding must sometimes find a second paper that maps the code to a molecule. No handling quantity, reconstitution procedure or route is given or implied.

What the literature has examined

A search for “chonluten” across PubMed and Europe PMC returns three indexed records. Only one of them is a study in which the compound was tested.

• The one primary study. Avolio et al. (2022, Int J Mol Sci, PMID 35408963) incubated the human THP-1 monocytic cell line with five Khavinson peptides — Epitalon, Vilon, Thymogen, Thymalin and Chonluten. Across all five they reported increased tyrosine phosphorylation of mitogen-activated cytoplasmic kinases and inhibition of LPS-stimulated TNF and IL-6 expression in terminally differentiated cells, plus reduced adhesion of treated THP-1 cells to LPS-activated HUVEC endothelial monolayers. For Chonluten specifically, the abstract singles out inhibition of TNF production by LPS-exposed monocytes, which the authors interpret as consistent with a documented TNF-tolerance mechanism. The work was performed at the University of Chieti-Pescara in Italy — but Khavinson, Mironova and Trofimova of the St Petersburg institute are co-authors, so this is not independent work.
• A review that names it in passing. Khavinson et al. (2020, Molecules, PMID 32987757) discuss peptides in the context of COVID-19 and lung protection. It is a review from the originating group, it proposes rather than demonstrates, and the immunomodulators it highlights by sequence are RKDVY, EW, KE and AEDG — not EDG.
• A transport review. Khavinson et al. (2022, Int J Mol Sci, PMID 35887081) argue that ultrashort peptides of this family are carried by proton-coupled oligopeptide transporters and L-type amino-acid transporters. This is the family-level review and modelling paper cited across the other pages in this cluster; it is not a transport measurement for Chonluten.

That is the complete indexed record located for this compound. There is no rodent study, no human report, and no work by any group without a St Petersburg co-author.

Evidence status — what is not established

Almost everything. There is no animal study of Chonluten in indexed sources. There is no human study of any design. There is no independent replication, because there is nothing yet to replicate: one cell-culture panel, co-authored by the originating institute, testing five compounds at once, is the entire primary evidence base.

The bronchial designation is not supported by any of the three papers above. The single primary study was carried out in a monocyte/macrophage line, not in lung tissue; the lung connection comes from the compound’s origin story and its name. That is worth stating plainly, because the tissue designation is the main thing said about this compound in secondary material.

Nor is the family’s central mechanism — sequence-specific peptide–DNA interaction driving gene expression — demonstrated for this compound at all. It has not been included in the binding, chromatin or gene-expression work that supports the hypothesis for other family members. The overview page sets out how far that hypothesis has been carried for the family as a whole, which is further than here but not as far as it is usually claimed.

Nothing on this page is a claim about what this compound does in a person. This page makes no efficacy, therapeutic, anti-inflammatory, bronchoprotective or other use claim of any kind, and the material is supplied for laboratory research use only — not for human or veterinary use.

Why this page is short: because the evidence is. Padding a three-citation literature into a long article is how a compound’s reputation gets ahead of its data, and this library’s standing rule is to write what exists and say when that is not much. When more is published, this page will grow.

How to verify this compound yourself

Mass spectrometry does the decisive work here, for the reason set out above: the family members are separated by one residue at a time, and the nearest lung-designated relative differs by about 127 Da. A certificate showing the expected mass for Glu-Asp-Gly (≈319 Da) distinguishes Chonluten from Bronchogen (AEDL, ≈446 Da), Pinealon (EDR, ≈418 Da) and Crystagen (EDP, ≈359 Da) at a glance. HPLC purity is reported as a percentage, but read it knowing that a tripeptide synthesis has very few opportunities to accumulate deletion sequences, so a high figure here is less informative than the same figure on a long peptide — which is exactly why the identity line matters more. Counter-ion and net peptide content are worth reading on any short, highly charged sequence, since a large share of vial mass can be counter-ion and water rather than peptide. See how to read a COA and how to verify peptide purity, and check a specific batch on the verify tool.

Research-grade sourcing and verification

Chonluten is not held in stock. It is listed on our sourcing catalogue as available to order — our supplier lists it, we have not bought it, and material of this kind typically takes about two to three weeks to reach us. For laboratory research use only, it is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation. Whatever one concludes about the biology, the identity of the material in the vial is documented rather than assumed — which matters more here than usual, given how many chemically similar compounds this family contains. Related pages: the bioregulator overview, Bronchogen, Crystagen and Vilon. This is sourcing and quality-assurance framing only.

Frequently asked questions

Literature cited

1. Avolio F, Martinotti S, Khavinson VK, et al. “Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.” Int J Mol Sci. 2022;23(7):3607. PMID 35408963. pubmed.ncbi.nlm.nih.gov/35408963. The only indexed primary study that tests Chonluten.
2. Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. “Peptides: Prospects for Use in the Treatment of COVID-19.” Molecules. 2020;25(19):4389. PMID 32987757. pubmed.ncbi.nlm.nih.gov/32987757 (review from the originating group).
3. Khavinson V, Linkova N, Kozhevnikova E, et al. “Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers.” Int J Mol Sci. 2022;23(14):7733. PMID 35887081. pubmed.ncbi.nlm.nih.gov/35887081 (family sequence and transport review).
4. Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, et al. “Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology.” Bull Exp Biol Med. 2015;159(5):685–688. PMID 26468022. pubmed.ncbi.nlm.nih.gov/26468022 (cited for contrast: this is Bronchogen, not Chonluten).
5. National Center for Biotechnology Information. “PubChem Compound Summary for CID 194641, Glu-Asp-Gly.” pubchem.ncbi.nlm.nih.gov/compound/194641 (formula, mass, CAS, “T-34 tripeptide” synonym).